Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–2015. Lancet Glob Health. 2018;6(7):e744–57. https://doi.org/10.1016/S2214-109X(18)30247-X.

Article  PubMed  PubMed Central  Google Scholar 

Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert R-R, et al. Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023;76(3):e1062–70. https://doi.org/10.1093/cid/ciac475.

Article  PubMed  Google Scholar 

Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J. 2021;40(10):944–51. https://doi.org/10.1097/inf.0000000000003277.

Article  PubMed  PubMed Central  Google Scholar 

Méroc E, Fletcher MA, Hanquet G, Slack MPE, Baay M, Hayford K, Gessner BD, Grant LR. Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine. Microorganisms. 2023;11(7):1816. https://doi.org/10.3390/microorganisms11071816.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Annex 3, Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. WHO Technical Report Series No 977, Sixtieth report, 2013. Geneva, Switzerland: World Health Organization; 2013. pp. 91–151.

Senders S, Klein NP, Tamimi N, Thompson A, Baugher G, Trammel J, et al. A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2024;43(6):596–603. https://doi.org/10.1097/INF.0000000000004334.

Article  PubMed  PubMed Central  Google Scholar 

Korbal P, Wysocki J, Jackowska T, Kline M, Tamimi N, Drozd J, et al. Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2024;43(6):587–95. https://doi.org/10.1097/INF.0000000000004300.

Article  PubMed  PubMed Central  Google Scholar 

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. https://doi.org/10.1016/S1473-3099(14)71081-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40(29):3963–74. https://doi.org/10.1016/j.vaccine.2022.05.011.

Article  CAS  PubMed  Google Scholar 

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine. 2015;33(2):359–66. https://doi.org/10.1016/j.vaccine.2014.11.011.

Article  CAS  PubMed  Google Scholar 

Dagan R, Poolman J, Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513–23. https://doi.org/10.1016/j.vaccine.2010.06.026.

Article  CAS  PubMed  Google Scholar 

Temple B, Licciardi P. Is it time to reconsider how higher valency pneumococcal conjugate vaccines are evaluated? Lancet Infect Dis. 2024. https://doi.org/10.1016/S1473-3099(23)00634-5.

Article  PubMed  Google Scholar 

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. immunogenicity and safety of 13-Valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. https://doi.org/10.1542/peds.2009-3027.

Article  PubMed  Google Scholar 

Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. https://doi.org/10.1016/S1473-3099(14)70822-9.

Article  CAS  PubMed  Google Scholar 

Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4):S66–76. https://doi.org/10.1097/INF.0b013e318199f8ef.

Article  PubMed  Google Scholar 

Feng S, McLellan J, Pidduck N, Roberts N, Higgins JPT, Choi Y, et al. Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data. eClinicalMedicine. 2023;61:102073. https://doi.org/10.1016/j.eclinm.2023.102073.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper—February 2019. Wkly Epidemiol Rec. 2019;94(08):85–103.

Google Scholar 

Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020. https://doi.org/10.1542/peds.2019-0377.

Article  PubMed  Google Scholar 

Hauser MI, Muscatello DJ, Soh ACY, Dwyer DE, Turner RM. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Vaccine. 2019;37(31):4246–55. https://doi.org/10.1016/j.vaccine.2019.06.039.

Article  CAS  PubMed  Google Scholar 

Mt-Isa S, Chumbley JR, Crawford EL, Banniettis N, Buchwald UK, Weaver J, et al. An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants. Expert Rev Vaccines. 2023;22(1):906–17. https://doi.org/10.1080/14760584.2023.2270039.

Article  CAS  PubMed  Google Scholar 

De Wals PJC. PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity. Can Commun Dis Rep. 2024;50(1–2):35–9.

Article  PubMed  PubMed Central  Google Scholar 

Carmona Martinez A, Prymula R, Miranda Valdivieso M, Otero Reigada MDC, Merino Arribas JM, Brzostek J, et al. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study. Vaccine. 2019;37(1):176–86. https://doi.org/10.1016/j.vaccine.2018.07.023.

Article  CAS  PubMed  Google Scholar 

Prymula R, Szenborn L, Silfverdal S-A, Wysocki J, Albrecht P, Traskine M, et al. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants. Vaccine. 2017;35(35, Part B):4603–11. https://doi.org/10.1016/j.vaccine.2017.07.008.

Article  CAS  PubMed  Google Scholar 

Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RMC, Zancolli M, Goldblatt D, et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS ONE. 2015;10(12): e0144739. https://doi.org/10.1371/journal.pone.0144739.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91. https://doi.org/10.1016/s0895-4356(97)00049-8.

Article  CAS  PubMed  Google Scholar 

Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023;41(5):1142–52. https://doi.org/10.1016/j.vaccine.2022.12.054.

Article  CAS  PubMed  Google Scholar 

Benfield T, Rämet M, Valentini P, Seppä I, Dagan R, Richmond P, et al. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine. 2023;41(15):2456–65. https://doi.org/10.1016/j.vaccine.2023.02.041.

Article  CAS  PubMed  Google Scholar 

Martinon-Torres F, Wysocki J, Szenborn L, Carmona-Martinez A, Poder A, Dagan R, et al. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023;41(21):3387–98.